These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26929412)

  • 1. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
    Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
    J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
    Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
    Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
    Sun J; Shi F; Yang N
    ACS Omega; 2019 Nov; 4(22):19573-19581. PubMed ID: 31788587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
    Colón-Bolea P; Crespo P
    Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
    Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
    Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
    Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
    Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
    Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
    SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
    Sun J; Li Z; Yang N
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
    Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
    Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
    Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
    Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
    Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
    Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
    Bernard BJ; Nigam N; Burkitt K; Saloura V
    Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
    Xu S; Zhong C; Zhang T; Ding J
    J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.
    Van Aller GS; Reynoird N; Barbash O; Huddleston M; Liu S; Zmoos AF; McDevitt P; Sinnamon R; Le B; Mas G; Annan R; Sage J; Garcia BA; Tummino PJ; Gozani O; Kruger RG
    Epigenetics; 2012 Apr; 7(4):340-3. PubMed ID: 22419068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
    Xu S; Wu J; Sun B; Zhong C; Ding J
    Nucleic Acids Res; 2011 May; 39(10):4438-49. PubMed ID: 21266482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
    Chandramouli B; Chillemi G
    J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
    Alnabulsi SM; Al-Shar'i NA
    Future Med Chem; 2019 May; 11(10):1107-1117. PubMed ID: 31280673
    [No Abstract]   [Full Text] [Related]  

  • 18. Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.
    Jiang Y; Trescott L; Holcomb J; Zhang X; Brunzelle J; Sirinupong N; Shi X; Yang Z
    J Mol Biol; 2014 Oct; 426(20):3413-25. PubMed ID: 24594358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
    Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
    Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
    Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
    Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.